GlaxoSmithKline $13 billion acquisition of Novartis consumer healthcare joint venture stake

27/3/2018

Private acquisition

Value:

$ 13 billion

Status:

Announced

Date:

27/3/2018

Overview:

GlaxoSmithKline (GSK) is acquiring Novartis's stake in their consumer healthcare joint venture for $13 billion,
The joint venture, which began in 2014, includes brands such as Nicotinell, Panadol Sensodyne and Voltaren.
According to Reuters the deal follows GSK's ending of its bid to acquire Pfizer’s consumer healthcare business.

Sam Duke

Jurisdictions:

Germany
Switzerland
United Kingdom

Deal type:

Private acquisition

Practice area:

M&A

Industry sectors:

Consumer goods and services
Healthcare

Firms:

Freshfields Bruckhaus Deringer

Party: Novartis (Seller)

Lawyers: Jennifer Bethlehem, Julian Long

Slaughter and May

Party: GlaxoSmithKline (Acquirer)

Lawyers: David Johnson, Simon Nicholls

Related deals